Targeting the undruggable oncogenic KRAS: the dawn of hope

Targeting the undruggable oncogenic KRAS: the dawn of hope

KRAS mutations are the drivers of various cancers, including non–small cell lung cancer, colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been made to inhibit KRAS mutants and oncogenic KRAS signaling using inhibitors. Recently, specific targeting of KRAS mutants wit...

Full description

Bibliographic Details
Main Authors: Hande Asimgil, Utku Ertetik, Nedim Can Çevik, Menar Ekizce, Alper Doğruöz, Muazzez Gökalp, Elif Arık-Sever, Rouzanna Istvanffy, Helmut Friess, Güralp Onur Ceyhan, Ihsan Ekin Demir
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-01-01
Series:JCI Insight
Online Access:https://doi.org/10.1172/jci.insight.153688

Internet

https://doi.org/10.1172/jci.insight.153688

Similar Items